Vaniqa
Developed to mitigate facial hair overgrowth to support epidermal texture and alleviate hair density.
- Category
- Skin Care
- Active ingredient
- Eflornithine
- Route
- Cutaneous use
- Form
- Cream
- Strengths
- 13.9% 15g
You will receive a quality generic equivalent of Vaniqa, depending on stock.
Prescription and consultation requirements for Vaniqa vary by destination and are determined by the fulfilment partner.
Vaniqa details
- Condition
- Excessive Facial Hair
- Alternative names
- eflornithine
- Therapeutic class
- Ornithine Decarboxylase Inhibitor
- Pharmacological class
- Topical Eflornithine
- Contraindications
- hypersensitivity to eflornithine
- Minor side effects
- local skin redness; burning; stinging
- Moderate side effects
- dry skin; pruritus; folliculitis
- Serious side effects
- severe localised contact dermatitis, requires immediate medical attention
- Dosage forms
- Cream
- Administration route
- Cutaneous use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Allergan
- Onset Time
- 4–8 weeks
- Storage instructions
- Store below 25°C. Do not freeze.
- Age restrictions
- Approved for children over twelve years and adults.
Patient summary
developed to mitigate facial hair overgrowth to support epidermal texture and alleviate hair density.
Mechanism of action
Irreversibly inhibits ornithine decarboxylase in hair follicles, stopping the synthesis of polyamines required for hair growth.
Pregnancy and breastfeeding
TGA Category C: Use if potential benefits outweigh risks. Breastfeeding: Consult a doctor.
What you will receive
Vaniqa is the originator brand name, made by Allergan. We use it to identify the medicine and are not affiliated with Allergan.
- The fulfilment partner confirms whether the exact brand or an equivalent containing Eflornithine is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.